Harvard Bioscience Inc has a consensus price target of $3 based on the ratings of 4 analysts. The high is $4 issued by Benchmark on March 10, 2023. The low is $2 issued by Benchmark on September 10, 2025. The 3 most-recent analyst ratings were released by Benchmark on September 10, 2025, May 13, 2025, and March 24, 2025, respectively. With an average price target of $3.17 between Benchmark, there's an implied 532.07% upside for Harvard Bioscience Inc from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
09/10/2025 | 299.2% | Benchmark | $3 → $2 | Maintains | Speculative Buy | |||
05/13/2025 | 498.8% | Benchmark | $4.5 → $3 | Maintains | Speculative Buy | |||
04/09/2025 | — | Keybanc | — | Downgrade | Overweight → Sector Weight | |||
03/24/2025 | 798.2% | Benchmark | $5.5 → $4.5 | Maintains | Speculative Buy | |||
06/22/2023 | 1297.21% | Benchmark | → $7 | Reiterates | Speculative Buy → Speculative Buy | |||
04/26/2023 | 1297.21% | Benchmark | $4 → $7 | Maintains | Buy | |||
04/26/2023 | 1297.21% | Keybanc | $5 → $7 | Maintains | Overweight | |||
03/10/2023 | 698.4% | Benchmark | → $4 | Reiterates | → Buy | |||
11/09/2022 | 898% | Keybanc | $7 → $5 | Maintains | Overweight |
The latest price target for Harvard Bioscience (NASDAQ:HBIO) was reported by Benchmark on September 10, 2025. The analyst firm set a price target for $2.00 expecting HBIO to rise to within 12 months (a possible 299.20% upside). 4 analyst firms have reported ratings in the last year.
The latest analyst rating for Harvard Bioscience (NASDAQ:HBIO) was provided by Benchmark, and Harvard Bioscience maintained their speculative buy rating.
There is no last upgrade for Harvard Bioscience
The last downgrade for Harvard Bioscience Inc happened on April 9, 2025 when Keybanc changed their price target from N/A to N/A for Harvard Bioscience Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Harvard Bioscience, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Harvard Bioscience was filed on September 10, 2025 so you should expect the next rating to be made available sometime around September 10, 2026.
While ratings are subjective and will change, the latest Harvard Bioscience (HBIO) rating was a maintained with a price target of $3.00 to $2.00. The current price Harvard Bioscience (HBIO) is trading at is $0.50, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.